MRP ₹108
(Inclusive of all Taxes)
₹14.6 Cashback (14%)
Extra 15% Off with Bank Offers
coupon
Available Offers
APLICICISave 19% on medicine orders above Rs. 1999 with ICICI credit Card
ONECARD5Flat 5% off on non- medicine orders above Rs. 700 with OneCard
ONECARD18Flat 18% Off on medicine orders above Rs. 1250 with OneCard
APOLLOMOBIKWIKUpto Rs. 500 cashback on payments above Rs. 999 with Mobikwik Wallet
APLAZYPAYUpto Rs. 300 cashback on 1st transaction of Rs. 500 and above with LazyPay
Author Details
Drug-Drug Interactions
No Drug - Drug interactions found in our data. We may lack specific data on this medicine and are actively working to update our database. Consult your doctor for personalized advice
Drug-Drug Interactions
Login/Sign Up
Drug-Food Interactions
No Drug - Food interactions found in our database. Some may be unknown. Consult your doctor for what to avoid during medication.
Drug-Food Interactions
Login/Sign Up
Drug-Diseases Interactions
FLUCONAZOLE-0.5%W/WOther diseases of liver
Severe
FLUCONAZOLE-0.5%W/WOther cardiac arrhythmias
Moderate
Drug-Diseases Interactions
Login/Sign Up
FLUCONAZOLE-0.5%W/WOther diseases of liver
Severe
How does the disease interact with Efcin 0.5% Dusting Powder:
Hepatotoxicity has only sometimes been linked to the usage of Efcin 0.5% Dusting Powder. There have been cases of reversible idiosyncratic hepatitis, cholestasis, and deadly fulminant hepatic failure; the latter generally affects people with substantial underlying medical disorders who are also taking several concurrent drugs. Patients with pre-existing hepatic problems should have periodic liver function tests done, especially during prolonged medication. If liver enzyme levels continue to rise or worsen, treatment should be stopped.
How to manage the interaction:
In patients with preexisting liver abnormalities, particularly during prolonged therapy, liver function tests should be done regularly. Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.
Hepatotoxicity has only sometimes been linked to the usage of Efcin 0.5% Dusting Powder. There have been cases of reversible idiosyncratic hepatitis, cholestasis, and deadly fulminant hepatic failure; the latter generally affects people with substantial underlying medical disorders who are also taking several concurrent drugs. Patients with pre-existing hepatic problems should have periodic liver function tests done, especially during prolonged medication. If liver enzyme levels continue to rise or worsen, treatment should be stopped.
How to manage the interaction:
In patients with preexisting liver abnormalities, particularly during prolonged therapy, liver function tests should be done regularly. Treatment should be withdrawn if persistent elevations or worsening of liver enzyme levels occur.
FLUCONAZOLE-0.5%W/WOther cardiac arrhythmias
Moderate
How does the disease interact with Efcin 0.5% Dusting Powder:
The QT interval on the ECG has been shown to be prolonged by some azole antifungals. During postmarketing experience, there have been a few isolated incidences of QT prolongation and torsade de pointes; these reports typically involved critically ill patients with a number of complicating risk factors, including structural cardiac disease, electrolyte problems, and concurrent medicines. Patients with illnesses that could cause proarrhythmic symptoms should take these medications cautiously. It is best to avoid using drugs that could potentially enhance the risk of cardiotoxicity concurrently.
How to manage the interaction:
It should be administered with caution to patients with heart problems. Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.
The QT interval on the ECG has been shown to be prolonged by some azole antifungals. During postmarketing experience, there have been a few isolated incidences of QT prolongation and torsade de pointes; these reports typically involved critically ill patients with a number of complicating risk factors, including structural cardiac disease, electrolyte problems, and concurrent medicines. Patients with illnesses that could cause proarrhythmic symptoms should take these medications cautiously. It is best to avoid using drugs that could potentially enhance the risk of cardiotoxicity concurrently.
How to manage the interaction:
It should be administered with caution to patients with heart problems. Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.
FLUCONAZOLE-0.5%W/WCare involving dialysis
Moderate
How does the disease interact with Efcin 0.5% Dusting Powder:
Hemodialysis effectively removes Efcin 0.5% Dusting Powder from the body. Following three hours of dialysis, it has been demonstrated that plasma levels of Efcin 0.5% Dusting Powder decrease by 50%. After hemodialysis, Efcin 0.5% Dusting Powder should be taken.
How to manage the interaction:
Efcin 0.5% Dusting Powder should be administered after hemodialysis.
Hemodialysis effectively removes Efcin 0.5% Dusting Powder from the body. Following three hours of dialysis, it has been demonstrated that plasma levels of Efcin 0.5% Dusting Powder decrease by 50%. After hemodialysis, Efcin 0.5% Dusting Powder should be taken.
How to manage the interaction:
Efcin 0.5% Dusting Powder should be administered after hemodialysis.
Author Details
Have a query?
